Hepatitis B Reactivation in a HBsAg-Negative, HBcAb-Positive Patient Receiving Fludarabine for the Treatment of Chronic Lymphocytic Leukaemia

Table 1

Serological HBV markers and HBV-DNA at diagnosis, during lamivudine treatment (Months 1, 3, and 6) and at 6-month followup (Month 12) after the end of lamivudine treatment.

	Onset	Month 1	Month 3	Month 6	Month 12
HBsAg	+	+	+	−	−
HBsAb	−	−	+	+	−
HBcAb-total	+	+	+	+	+
HBcAb-IgM	−	−	−	−	−
HBeAg	+	+	−	−	−
HBeAb	−	−	−	+	+
HBV-DNA; (UI/mL)	7.06 × 10^6	5,96 × 10^3	1.4 × 10^2	<12	<12

Legend: HBsAg: Hepatitis B surface antigen; HBsAb: Hepatitis B surface antibodies; HBcAb-total: Hepatitis B core antibodies (total); HBcAb-IgM: Hepatitis B core antibodies (IgM only); HBeAg: Hepatitis B e antigen; HBeAb: Hepatitis B e antibodies.